Investment
Features
FeesSafety
Academy
More
Pluang+

Compare National Beverage Corp. (FIZZ) vs Mesoblast Limited (MESO) Price & Performance

National Beverage Corp.Trade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

National Beverage Corp. vs Mesoblast Limited — how do they compare? National Beverage Corp. trades at $30.9 (market cap $2.91B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: National Beverage Corp. is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.

FIZZMESO
Market Cap
$2.91B$2.16B
Sector
Consumer CyclicalTechnology
52-Week High
$46.75$20.96
52-Week Low
$30.53$12.88
Enterprise Value
$2.62B$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

National Beverage Corp.

FIZZ trades at $32.13, up 0.53% today, with neutral technical signals and mixed earnings performance. The company reported $1.20B revenue and $186.82M net income for 2025, maintaining strong profitability margins. Recent news highlights a special $3.25 dividend announcement amid concerns about LaCroix brand stagnation and competitive pressures.

The stock faces headwinds from declining volumes and muted growth prospects, offset by shareholder returns via dividends. Analyst sentiment is cautious with 50% sell ratings. Key risks include consumer weakness and tariff impacts, while valuation at 15.84x P/E appears reasonable given current fundamentals.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About National Beverage Corp.

National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.

Read more on FIZZ

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO